Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

targeted α-therapy

  • First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted <sup>212</sup>Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer
    Open Access
    First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer
    Kjetil Berner, Eivor Hernes, Monika Kvassheim, Mona-Elisabeth Revheim, Julie Bastiansen, Silje Selboe, Charlotte L. Bakken, Simen R. Grønningsæter, Øyvind S. Bruland, Roy H. Larsen, Lily Bouzelmat, Vicki L. Jardine and Caroline Stokke
    Journal of Nuclear Medicine May 1, 2025, 66 (5) 732-738; DOI: https://doi.org/10.2967/jnumed.124.269299
  • Side-by-Side Comparison of the In Vivo Performance of [<sup>212</sup>Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds
    Open Access
    Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds
    Amal Saidi, Tania A. Stallons, Amy G. Wong, Aaron T. Schatzmann, Ugur Soysal and Julien J. Torgue
    Journal of Nuclear Medicine March 1, 2025, 66 (3) 391-397; DOI: https://doi.org/10.2967/jnumed.124.268345
  • Preclinical Evaluation of <sup>226</sup>Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy
    You have access
    Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy
    Helena Koniar, Luke Wharton, Aidan Ingham, Ana Paulina Morales Oliver, Helen Merkens, Cristina Rodríguez-Rodríguez, Peter Kunz, Valery Radchenko, Hua Yang, Arman Rahmim, Carlos Uribe and Paul Schaffer
    Journal of Nuclear Medicine November 1, 2024, 65 (11) 1762-1768; DOI: https://doi.org/10.2967/jnumed.124.267999
  • Preclinical Investigation of [<sup>212</sup>Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model
    Open Access
    Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model
    Amal Saidi, Tania A. Stallons, Amy G. Wong and Julien J. Torgue
    Journal of Nuclear Medicine November 1, 2024, 65 (11) 1769-1775; DOI: https://doi.org/10.2967/jnumed.124.268101
  • Development of a <sup>213</sup>Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates
    You have access
    Development of a 213Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates
    Aidan A. Bender, Emily K. Kirkeby, Donna J. Cross, Satoshi Minoshima, Andrew G. Roberts and Tara E. Mastren
    Journal of Nuclear Medicine September 1, 2024, 65 (9) 1467-1472; DOI: https://doi.org/10.2967/jnumed.124.267482
  • Development and Preclinical Evaluation of [<sup>211</sup>At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer
    You have access
    Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer
    Mohamed El Fakiri, Nawal Ayada, Marius Müller, Lars Hvass, Teodor H. Gamzov, Anne Skovsbo Clausen, Nicolas M. Geis, Nils Steinacker, Ellinor Hansson, Sture Lindegren, Emma Aneheim, Holger Jensen, Ann-Christin Eder, Andreas I. Jensen, Christian B.M. Poulie, Andreas Kjaer, Matthias Eder and Matthias M. Herth
    Journal of Nuclear Medicine April 1, 2024, 65 (4) 593-599; DOI: https://doi.org/10.2967/jnumed.123.267043
  • <sup>212</sup>Pb-Pretargeted Theranostics for Pancreatic Cancer
    You have access
    212Pb-Pretargeted Theranostics for Pancreatic Cancer
    David Bauer, Lukas M. Carter, Mohamed I. Atmane, Roberto De Gregorio, Alexa Michel, Spencer Kaminsky, Sebastien Monette, Mengshi Li, Michael K. Schultz and Jason S. Lewis
    Journal of Nuclear Medicine January 1, 2024, 65 (1) 109-116; DOI: https://doi.org/10.2967/jnumed.123.266388
  • <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior <sup>223</sup>Ra (RALU Study)
    Open Access
    177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)
    Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P. Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Kim M. Pabst, Milena Kurtinecz, Anja Schmall, Frank Verholen and Oliver Sartor
    Journal of Nuclear Medicine December 1, 2023, 64 (12) 1925-1931; DOI: https://doi.org/10.2967/jnumed.123.266125
  • Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with <sup>89</sup>Zr or <sup>211</sup>At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
    Open Access
    Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
    Tadashi Watabe, Kazuya Kabayama, Sadahiro Naka, Ryuku Yamamoto, Kazuko Kaneda, Satoshi Serada, Kazuhiro Ooe, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Kenta Kurimoto, Takanori Kobayashi, Eku Shimosegawa, Noriyuki Tomiyama, Koichi Fukase and Tetsuji Naka
    Journal of Nuclear Medicine December 1, 2023, 64 (12) 1949-1955; DOI: https://doi.org/10.2967/jnumed.123.266313
  • Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>223</sup>Ra: PARABO, a Prospective, Noninterventional Study
    Open Access
    Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra: PARABO, a Prospective, Noninterventional Study
    Holger Palmedo, Hojjat Ahmadzadehfar, Susanne Eschmann, Andreas Niesen, Johann Schönberger, Vahé Barsegian, Knut Liepe, Felix M. Mottaghy, Rongjin Guan, Joerg Pinkert, Per Sandström and Ken Herrmann
    Journal of Nuclear Medicine September 1, 2023, 64 (9) 1392-1398; DOI: https://doi.org/10.2967/jnumed.123.265557

Pages

  • Next
  • 1
  • 2
SNMMI

© 2025 SNMMI

Powered by HighWire